Biogen Inc.
BIIBCompany Overview
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Country
US
Market Cap
$37.71B
Last Fiscal Year
2023
Final Shariah Status
Passed
Compliance Analysis Overview
Shariah Compliance Benchmarks:
- Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
- Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
Business Compliance
0.98%
passed
Liabilities Compliance
19.47%
passed
Final Shariah Status
Passed
This stock meets all Shariah compliance criteria according to AAOIFI standards.
Stock Information
| Name | Biogen Inc. |
| Ticker | BIIB |
| Main Business | Biopharmaceutical company (treat multiple sclerosis (MS), treatment for spinal muscular atrophy (SMA) and co-developed two treatments to address a defining pathology of Alzheimer’s disease.) |
| Type | Securities |
| Industry | Drug Manufacturers—General |
| Country | US |
| Market Cap | $37.71 B |
Shariah Analysis Breakdown
Business compliance Breakdown
| Revenue Segment | Value ($M) | Non-Compliant ($M) | Reason |
|---|---|---|---|
| Product, net | $7,987.0 | $0.0 | - |
| Revenue from anti-CD20 therapeutic programs | $1,700.0 | $0.0 | - |
| Other | $485.0 | $0.0 | - |
| (Gain) loss on fair value remeasurement of contingent consideration | $209.0 | $0.0 | - |
| Gain on sale of building | $503.0 | $0.0 | - |
| Other (income | $108.2 | $108.2 | realized gains and losses on marketable debt securities and marketable equity securities and venture capital funds. |
| Total | $10,992.2 | $108.2 | 0.98% (passed) |
Liabilities Compliance Breakdown
| Liability Item | Value ($M) | % of Market Cap |
|---|---|---|
| current debt and capital lease obligation | $150,000,000.0 | 0.40% |
| long term debt and capital lease obligation | $7,190,000,000.0 | 19.07% |
| Total Interest-Bearing Debt | $7,340,000,000.0 | 19.47% |
| Market Capitalization | $37,707,964,400.0 | 100.00% |
| Compliance Status | Threshold: 33% | passed |